LOCATED IN key US and international markets, including Europe, Asia and the Americas, these facilities are optimised for speed and short-term storage between air and ground movements, while maintaining specific temperature requirements.

The announcement strengthens UPS’s global cold-chain network as demand grows for medicines requiring strict temperature ranges of 2 to 8 degrees Celsius, 15 to 25 degrees Celsius and frozen.

Industry demand for temperature-sensitive biologics is projected to expand at an 8.3% compound annual growth rate through 2033, reaching an estimated $39.1 billion, according to Growth Market Reports.

All facilities are compliant with IATA CEIV Pharma certification.

UPS’s cross-dock expansion builds on a long-term investment in complex healthcare logistics, strengthened through acquisitions including Bomi Group, Frigo Trans and BPL in Europe and Andlauer Healthcare Group in North America. More recently, UPS expanded its Incheon, Korea air hub to support fast-growing pharmaceutical trade flows.

Kate Gutmann at UPS said: “We understand we’re doing more than moving packages. We are helping patients access the medications and treatments they need. A single integrated network eliminates handoffs between providers, reducing risk and increasing control.”